Replies to post #131922 on Biotech Values

[DewDiligence]

I will get back to you re wildcards - have been thinking about this a good deal and so far do not have a compelling alternative…

If the “wildcard” alternatives are not compelling, why do they rank ahead of MRK and, especially, SNY on your list?

[DewDiligence]

…we hear at least as much about Sandoz's supposed [FoB] priorities and strategies from MNTA as we do from NVS…

The public comments on this subject by the two companies have been remarkably consistent.